MARKET

FOMX

Foamix
FOMX
NASDAQ
Delisted
P/E
P/S
P/B
MARKET CAP
-1.7602
140.57
3.414
184,130,096.28
About FOMX
Foamix Pharmaceuticals Ltd. is a clinical-stage pharmaceutical company. The Company is engaged in the development and commercialization of foam-based formulations, using its technology, which includes its foam platforms. It is focused on developing and commercializing its minocycline foam for the treatment of acne, rosacea and other skin conditions. Its product candidates include FMX101, FMX102, FMX103 and FDX104. Its lead product candidate, FMX101, is a topical foam formulation of the antibiotic minocycline for the treatment of moderate-to-severe acne. FMX102 is a formulation of its minocycline foam being developed for the treatment of impetigo. FMX103 is a topical foam formulation of minocycline for the treatment of moderate-to-severe Papulopustular rosacea. FDX104 is a topical foam formulation of the antibiotic doxycycline for the treatment of severe acne-like rashes induced by chemotherapy. It has conducted one Phase II clinical trial for each of FMX101, FMX102, FMX103 and FDX104.
More

FOMX News

More
Menlo's partner LEO Pharma remedies Finacea Foam supply issues
seekingalpha · 04/02 18:37
Menlo Therapeutics and Foamix Pharmaceuticals Complete Merger, Creating a Combined Company Focused on the Development and Commercialization of Therapeutics for Dermatologic Indications
PR Newswire · 03/09 13:18
Menlo Therapeutics up 20% ahead of Foamix merger & key data readout
Seeking Alpha - Article · 03/06 18:04
3 Top Biotech Stocks With Major Catalysts Approaching
TipRanks · 03/05 16:09
Menlo Is A Good Bet Reflecting The Upcoming Catalysts
Seeking Alpha - Article · 03/03 17:32
Foamix Pharmaceuticals to Present at the Cowen and Company’s 40th Annual Health Care Conference
GlobeNewswire · 02/25 13:00
Foamix Pharma Reports Integrated Efficacy Results From FMX103 1.5% Topical Minocycline Foam Phase 3 Program For Rosacea
Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) ("Foamix" or the "Company"), a specialty pharmaceutical company focused on developing and commercializing proprietary topical therapies to address unmet
Benzinga · 02/18 21:09
Foamix Announces Integrated Efficacy Results from the FMX103 1.5% Topical Minocycline Foam Phase 3 Program for Rosacea
GlobeNewswire · 02/18 13:00

Hot Stocks

Symbol
Price
%Change

Webull offers kinds of Foamix stock information, including NASDAQ:FOMX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, FOMX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading FOMX stock methods without spending real money on the virtual paper trading platform.